Ereky K. Biotechnology of meat, fat and milk production in an agricultural large-scale farm. Berlin, Germany: P. Parey; 1919.
US FDA. Celebrating a milestone: FDA's approval of first genetically-engineered product. http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SelectionsFromFDLIUpdateSeriesonFDAHistory/ucm081964.htm (2009). Accessed 9 Feb 2017.
Astellas Pharm US announces discontinuation of manufacturing for Amevive [press release]. Available at http://www.the-dermatologist.com/content/astellas-pharma-us-announces-discontinuation-manufacturing-amevive. Accessed 1 Feb 2017.
Amgen Inc. The power of biologics. Avaialble at http://www.amgenbiosimilars.com/the-basics/the-power-of-biologics/. Accessed 6 Feb 2017.
Rathore N, Rajan RS. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog. 2008;24(3):504–14.
Ho K. Manufacturing process of biologics. International conference on harmonisation of technical requirements for registration of Pharmaceuticals for Human Use; May 30, 2011; Kuala Lumpur, Malaysia.
Lai T, Yang Y, Ng SK. Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel). 2013;6(5):579–603.
Arnold JN, Wormald MR, Sim RB, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21–50.
Dumont J, Euwart D, Mei B, et al. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36(6):1110–22.
Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24(10):1241–52.
Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins. J Pharm Sci. 2015;104(6):1866–84.
Lubiniecki A, Volkin DB, Federici M, et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. Biologicals. 2011;39(1):9–22.
Wright B, Bruninghaus M, Vrabel N, et al. A novel seed-train process: using high-density cell banking, a disposable bioreactor, and perfusion technologies. Available at: http://www.bioprocessintl.com/upstream-processing/upstream-single-use-technologies/novel-seed-train-process-using-high-density-cell-banking-disposable-bioreactor-perfusion-technologies/ Accessed 4 Feb 2017: BioProcess International; 2015.
Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053–8.
Liu HF, Ma J, Winter C, et al. Recovery and purification process development for monoclonal antibody production. MAbs. 2010;2(5):480–99.
US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Available at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf (2015). Accessed 4 Feb 2017.
FDA approves first biosimilar product Zarxio [press release]. Silver Spring, MD: Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. (2015). Accessed 4 Feb 2017.
FDA approves Inflectra, similar to Remicade [press release]. Silver Spring, MD: Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. (2016). Accessed 4 Feb 2017.
FDA approves Erelzi, a biosimilar to Enbrel [press release]. Silver Spring, MD: Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518639.htm. (2016). Accessed 8 Feb 2017.
FDA approves amjevita, a biosimilar to Humira [press release]. Silver Spring, MD: Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522243.htm. (2016). Accessed 4 Feb 2017.
Pro Pharma Communications International. GaBI online-generics and biosimilars initiative. Biosimilars use in Europe Mol, Belgium: Available at: http://www.gabionline.net/Reports/Biosimilars-use-in-Europe. (2011). Accessed 4 Feb 2017.
Zelenetz A, Ahmed I, Braud EL, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(Suppl 4):S1–S22.
Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:412–9.
Declerck P, Farouk-Rezk M, Rudd PM. Biosimilarity versus manufacturing change: two distinct concepts. Pharm Res. 2016;33(2):261–8.
US FDA. New Drug Application (NDA). Silver Spring, MD: Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/default.htm. (2016). Accessed 4 Feb 2017.
Federal Register. Guidance for industry on scale-up post-approval changes: manufacturing equipment Addendum. Available at: https://www.gpo.gov/fdsys/pkg/FR-2014-12-02/pdf/2014-28256.pdf. (2014). Accessed 4 Feb 2017.
International Conference on Harmonisation. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process. Avaialble at http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. (2004). Accessed 8 Feb 2017.